A clinical feasible stem cell encapsulation ensures an improved wound healing.


Journal

Biomedical materials (Bristol, England)
ISSN: 1748-605X
Titre abrégé: Biomed Mater
Pays: England
ID NLM: 101285195

Informations de publication

Date de publication:
06 02 2023
Historique:
received: 21 10 2022
accepted: 26 01 2023
pubmed: 27 1 2023
medline: 8 2 2023
entrez: 26 1 2023
Statut: epublish

Résumé

Cell encapsulation has proven to be promising in stem cell therapy. However, there are issues needed to be addressed, including unsatisfied yield, unmet clinically friendly formulation, and unacceptable viability of stem cells after cryopreservation and thawing. We developed a novel biosynsphere technology to encapsulate stem cells in clinically-ready biomaterials with controlled microsphere size. We demonstrated that biosynspheres ensure the bioviability and functionality of adipose-derived stromal cells (ADSCs) encapsulated, as delineated by a series of testing procedures. We further demonstrated that biosynspheres protect ADSCs from the hardness of clinically handling such as cryopreservation, thawing, high-speed centrifugation and syringe/nozzle injection. In a swine full skin defect model, we showed that biosynspheres were integrated to the destined tissues and promoted the repair of injured tissues with an accelerating healing process, less scar tissue formation and normalized deposition of collagen type I and type III, the ratio similar to that found in normal skin. These findings underscore the potential of biosynsphere as an improved biofabrication technology for tissue regeneration in clinical setting.

Identifiants

pubmed: 36701809
doi: 10.1088/1748-605X/acb67a
doi:

Substances chimiques

Collagen Type I 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Creative Commons Attribution license.

Auteurs

Xiao Zuo (X)

Regenerative Medicine Research Center, Sichuan University West China Hospital, Chengdu, Sichuan 610041, People's Republic of China.
Sichuan 3D Bio-Printing Institute, Chengdu, Sichuan 611731, People's Republic of China.
Revotek Co., Ltd, Chengdu, Sichuan 611731, People's Republic of China.

Xia Jiang (X)

Regenerative Medicine Research Center, Sichuan University West China Hospital, Chengdu, Sichuan 610041, People's Republic of China.

Yaya Zhang (Y)

Sichuan 3D Bio-Printing Institute, Chengdu, Sichuan 611731, People's Republic of China.
Department of Physiology, University of Tennessee Health Science Center, Memphis, TN 38163, United States of America.

Yushi Huang (Y)

Revotek Co., Ltd, Chengdu, Sichuan 611731, People's Republic of China.

Ning Wang (N)

Revotek Co., Ltd, Chengdu, Sichuan 611731, People's Republic of China.

Ping Zhu (P)

Revotek Co., Ltd, Chengdu, Sichuan 611731, People's Republic of China.

Y James Kang (YJ)

Regenerative Medicine Research Center, Sichuan University West China Hospital, Chengdu, Sichuan 610041, People's Republic of China.
Sichuan 3D Bio-Printing Institute, Chengdu, Sichuan 611731, People's Republic of China.
Department of Physiology, University of Tennessee Health Science Center, Memphis, TN 38163, United States of America.

Articles similaires

Animals Natural Killer T-Cells Mice Adipose Tissue Lipid Metabolism
Curcumin Spinal Cord Injuries Humans Animals Neural Stem Cells
Humans Stroke Female Male Cross-Sectional Studies
Obesity Machine Learning Animals Biomarkers Computational Biology

Classifications MeSH